TL-118

N/A

Report date: 2024/07/22 10:26:21
NME

Base Information

Drug NameTL-118
Drug Alias NameTL118TL-118
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTropomyosin-related kinase inhibitors
TargetsTropomyosin-related kinase
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCentral Nervous System Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou Teligene Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSuzhou Teligene Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisCentral Nervous System Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A